New York, USA, April 20, 2023 (GLOBE NEWSWIRE) -- Neuroblastoma Market to Grow at a Substantial Growth Rate, Predicts DelveInsight | Y-mabs therapeutics, Clarity Pharmaceuticals, K C Pharmaceuticals, Exelixis, Eli Lilly and Company, Innervate Radiopharmaceuticals, and Others Expected to Propel Market
The neuroblastoma market is expected to surge in the coming years in the seven major markets owing to the expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and a further improvement in the diagnosis rate.
DelveInsight’s Neuroblastoma Market Insights report includes a comprehensive understanding of current treatment practices, neuroblastoma emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Neuroblastoma Market Report
- As per DelveInsight analysis, the neuroblastoma market is expected to grow positively owing to several underline factors during the study period (2019–2032).
- According to DelveInsight analysis, it was found that neuroblastoma affects males slightly more than females.
- Leading neuroblastoma companies such as Y-mabs therapeutics, Clarity Pharmaceuticals, K C Pharmaceuticals, Exelixis, Eli Lilly and Company, Innervate Radiopharmaceuticals LLC, Jubilant DraxImage Inc., Curis, Inc., Valent Technologies, LLC, Elicio Therapeutics, Cellectar Biosciences, Inc., Pfizer, Hoffmann-La Roche, Endeavor Biomedicines, Inc., and others are developing novel neuroblastoma drugs that can be available in the neuroblastoma market in the coming years.
- Some of the key therapies for neuroblastoma treatment include Omburtamab, SARTATE, Eflornithine, Cabozantinib, LY3295668 Erbumine, 18F-MFBG, 131-MIBG + Vorinostat, CUDC-907, VAL-413, DFMO + Bortezomib, ELI-002 7P, CLR 131, Lorlatinib, Crizotinib, Entrectinib, ENV-101 (taladegib), and others.
- Several neuroblastoma therapies are awaiting approval, while some therapies are in the advanced stages of development.
Discover which therapies are expected to grab the major neuroblastoma market share @ Neuroblastoma Market Report
Neuroblastoma Overview
Neuroblastoma is an embryonic cancer of the sympathetic nervous system that develops from neuroblasts. It is taken from two words: “neuro” signifies nerves, and “blastoma” is a tumor that affects immature or developing cells. It is caused by sympathetic nervous system tissue in the adrenal medulla and paraspinal or periaortic areas. Neuroblastoma is occasionally caused by a gene mutation (change) handed down from parent to child. Children with specific gene mutations or genetic diseases should be monitored for neuroblastoma symptoms until they reach age 10.
Neuroblastoma symptoms can include abdominal mass, which can be felt during an examination or seen as a large abdomen, dark circles around the eyes, unexplained fevers, persistent diarrhea, bone pain, weight loss, weariness, and many others. Neuroblastoma frequently spreads to bone marrow. If catecholamine levels in the blood or urine are elevated, identifying cancer cells in a bone marrow sample is sufficient for neuroblastoma diagnosis.
Neuroblastoma Epidemiology Segmentation
As per the DelveInsight estimates, the United States has the highest incident population of neuroblastoma.
The neuroblastoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Incident Cases of Neuroblastoma
- Gender-specific Incident Cases of Neuroblastoma
- Age-specific Incident Cases of Neuroblastoma
- Incident Patient Population of Neuroblastoma by Risk Groups
Download the report to understand which factors are driving neuroblastoma epidemiology trends @ Neuroblastoma Epidemiological Insights
Neuroblastoma Treatment Market
Neuroblastoma patients might get a variety of treatments. Some neuroblastoma treatments are mainstream, while others are being investigated in clinical studies. A child’s risk category mostly determines neuroblastoma treatment. There are four standard risk groups: low risk, middle risk, high risk, and recurrent neuroblastoma. In general, younger children with smaller tumors are in the lower-risk groups, while older children, children with tumors that have spread throughout the body, and children whose tumors exhibit unfavorable traits or additional copies of the MYCN gene are in the high-risk group. Some infants with neuroblastoma that have progressed throughout the body may still be considered low risk, particularly if their tumor lacks additional copies of MYCN or other unfavorable characteristics.
Surgery is the first step in treatment for neuroblastoma patients in the low and intermediate-risk groups, followed by chemotherapies, radiation, and retinoid therapies (isotretinoin). Radiation and retinoid treatments are only utilized in intermediate-risk patients. In high-risk neuroblastoma patients, the discussed medicines, coupled with stem cell transplantation and immunotherapies (Qarziba and Unituxin), are also recommended.
To know more about neuroblastoma treatment, visit @ Neuroblastoma Treatment Drugs
Key Neuroblastoma Therapies and Companies
- Omburtamab: Y-mabs therapeutics
- SARTATE: Clarity Pharmaceuticals
- Eflornithine: K C Pharmaceuticals
- Cabozantinib: Exelixis
- LY3295668 Erbumine: Eli Lilly and Company
- 18F-MFBG: Innervate Radiopharmaceuticals LLC
- 131-MIBG + Vorinostat: Jubilant DraxImage Inc.
- CUDC-907: Curis, Inc.
- VAL-413: Valent Technologies, LLC
- DFMO + Bortezomib: K C Pharmaceuticals Inc.
- ELI-002 7P: Elicio Therapeutics
- CLR 131: Cellectar Biosciences, Inc.
- Lorlatinib: Pfizer
- Crizotinib: Pfizer
- Entrectinib: Hoffmann-La Roche
- ENV-101 (taladegib): Endeavor Biomedicines, Inc.
Learn more about the FDA-approved drugs for neuroblastoma @ Drugs for Neuroblastoma Treatment
The dynamics of the neuroblastoma market are anticipated to change in the coming years. The neuroblast may be caused by immature cell development or a mutation in the gene that controls cell proliferation. more juvenile cancer cases, more research on neuroblastoma treatment, and increased cancer treatment spending will likely fuel neuroblastoma market expansion over the forecast period. Moreover, as our understanding of neuroblastoma biology grows, so are our methods of treating the disease. Improved risk stratification and the use of predictive biomarkers will aid in therapy selection for patients with neuroblastoma, and future medicines are likely to have higher efficacy and lower toxicity, thus propelling the neuroblastoma market growth. Furthermore, the neuroblastoma pipeline is highly robust; many possible therapies are being studied for neuroblastoma treatment, and it is safe to assume that the therapeutic space will substantially impact the neuroblastoma market throughout the forecast period.
However, certain factors may affect the growth of the neuroblastoma market. Neuroblastoma can be almost benign in some children, with spontaneous regression, but most older individuals have a high-risk illness that is usually deadly, despite the finest current treatments. Moreover, the neuroblastoma market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the neuroblastoma market growth.
| Report Metrics | Details |
| Study Period | 2019–2032 |
| Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Base Year | 2019 |
| Key Neuroblastoma Companies | Y-mabs therapeutics, Clarity Pharmaceuticals, K C Pharmaceuticals, Exelixis, Eli Lilly and Company, Innervate Radiopharmaceuticals LLC, Jubilant DraxImage Inc., Curis, Inc., Valent Technologies, LLC, Elicio Therapeutics, Cellectar Biosciences, Inc., Pfizer, Hoffmann-La Roche, Endeavor Biomedicines, Inc., and others |
| Key Neuroblastoma Therapies | Omburtamab, SARTATE, Eflornithine, Cabozantinib, LY3295668 Erbumine, 18F-MFBG, 131-MIBG + Vorinostat, CUDC-907, VAL-413, DFMO + Bortezomib, ELI-002 7P, CLR 131, Lorlatinib, Crizotinib, Entrectinib, ENV-101 (taladegib), and others |
Scope of the Neuroblastoma Market Report
- Therapeutic Assessment: Neuroblastoma current marketed and emerging therapies
- Neuroblastoma Market Dynamics: Attribute Analysis of Emerging Neuroblastoma drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Neuroblastoma Market Access and Reimbursement
Discover more about neuroblastoma drugs in development @ Neuroblastoma Clinical Trials
Table of Contents
| 1. | Neuroblastoma Market Key Insights |
| 2. | Neuroblastoma Market Report Introduction |
| 3. | Neuroblastoma Market Overview at a Glance |
| 4. | Neuroblastoma Market Executive Summary |
| 5. | Disease Background and Overview |
| 6. | Neuroblastoma Treatment and Management |
| 7. | Neuroblastoma Epidemiology and Patient Population |
| 8. | Patient Journey |
| 9. | Neuroblastoma Marketed Drugs |
| 10. | Neuroblastoma Emerging Drugs |
| 11. | Seven Major Neuroblastoma Market Analysis |
| 12. | Neuroblastoma Market Outlook |
| 13. | Potential of Current and Emerging Therapies |
| 14. | KOL Views |
| 15. | Neuroblastoma Market Drivers |
| 16. | Neuroblastoma Market Barriers |
| 17. | Unmet Needs |
| 18. | SWOT Analysis |
| 19. | Appendix |
| 20. | DelveInsight Capabilities |
| 21. | Disclaimer |
| 22. | About DelveInsight |
Related Reports
Neuroblastoma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key neuroblastoma companies, including Clarity Pharmaceuticals Ltd, Eli Lilly and Company, Laboratorio Elea Phoenix S.A., PersonGen BioTherapeutics (Suzhou) Co., Ltd., among others.
Neuroblastoma Epidemiology Forecast
Neuroblastoma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted neuroblastoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Pediatric Neuroblastoma Pipeline
Pediatric Neuroblastoma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key pediatric neuroblastoma companies, including GE Healthcare, Millennium Pharmaceuticals, Genentech, Actuate Therapeutics, among others.
Pediatric Neuroblastoma Market
Pediatric Neuroblastoma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key pediatric neuroblastoma companies including GE Healthcare, Millennium Pharmaceuticals, Genentech, Actuate Therapeutics, among others.
Pediatric Neuroblastoma Epidemiology
Pediatric Neuroblastoma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted pediatric neuroblastoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Other Trending Reports
Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Neuroblastoma Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuroblastoma Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
